On January 30, 2026, Lexeo Therapeutics, Inc. announced the departure of Dr. Adler as Head of Research, effective February 1, 2026, with a consulting agreement worth up to $62,500 during his advisory period. His equity awards will continue to vest, and he has an extended period for stock option exercises.